FdaApplication
NDA 215272
Identifiers
- fda_app_no: NDA215272
Properties
| Property | Value |
|---|---|
| applicant_name | ORGANON LLC |
| application_type | NDA |
| approval_date | 2022-05-23 |
Revenue by product
VTAMA
| Period | Revenue |
|---|---|
| Q2 2026 | $35.0M |
| Q1 2026 | $25.0M |
| Q4 2025 | $39.0M |
| Q3 2025 | $34.0M |
| Q2 2025 | $31.0M |
| Q1 2025 | $24.0M |
| Q4 2024 | $12.0M |
| Q3 2024 | $0.0M |
| Q2 2024 | $0.0M |
| Q1 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VTAMA | TAPINAROF | 1% | CREAM;TOPICAL |
1 product